Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
SCHOTT India acquitted of all Anti-Competitive Conduct in a case against CCI - The Pharma Times | Pharma & Health Care News Portal
Categories: Company News

SCHOTT India acquitted of all Anti-Competitive Conduct in a case against CCI


Competition Appellate Tribunal rules in favor of SCHOTT India against 
the Competition Commission of India and Kapoor Glass Pvt. Ltd.

The Tribunal condemns Kapoor Glass’ act of forging SCHOTT India glass tubes as a direct hazard to human lives.
 

New Delhi, April 17, 2014 – The Competition Appellate Tribunal (CAT) has cleared SCHOTT India from all penalties and charges made under an Order of the Competition Commission of India (CCI) that had been initiated by Kapoor Glass Pvt. Limited. SCHOTT India was falsely accused of abusing its strong position in the glass tubes market and granting discriminatory pricing and other favorable terms to its affiliated entity, SCHOTT KAISHA as compared to other converters in the market.

 

In July 2010, Kapoor Glass Pvt. Limited (Kapoor), a converter and former manufacturer of Glass Tubes, filed information with the CCI in which it complained of alleged anti-competitive practices of SCHOTT India which affected the competition in the market for Neutral USP Type I Borosilicate Glass Tubes as well as in the downstream market for the Containers. After the CCI initially decided against SCHOTT India, the case was referred to CAT.

 

In the CAT judgment, it was pointed out that SCHOTT KAISHA was a vertically integrated subsidiary of the SCHOTT Group and that the quantity purchased by SCHOTT KAISHA by far exceeded the purchases of any other converter company. Better terms for SCHOTT KAISHA were therefore justified. The tribunal also clarified that there was no negative impact on the downstream market for glass tube containers and that the ultimate consumer did not suffer any damage as alleged in Kapoor’s appeal.

 

The judges refuted CCI’s argument that favorable prices of SCHOTT India for SCHOTT KAISHA had resulted in reduced profit margins for the other converters and deprived them of their chance to grow. In addition, they rejected the allegations by Kapoor that SCHOTT’s Standard Trademark License Agreement was unfair and restrictive to the detriment of other converters.

 

Finally, CAT clearly denied any obligation of SCHOTT India to make deliveries to Kapoor, which had been stopped in 2008. The special Tribunal established that Kapoor had once forged SCHOTT India’s labels and thus committed a clear and unabashed breach of trademarks. It condemned such act of forging as the relevant products had a direct relation with human lives and serious consequences could ensue on account of usage of inferior quality of glass tubes. The Tribunal stated that it could not imagine the seriousness of the consequences if Kapoor could pass off inferior quality glass with the help of such faked labels. CCI Newswire

The Pharma Times News Bureau

Recent Posts

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

2 days ago

Milestone set in Indian Medical History – SSI Mantra Surgical Robotic System Performs the First-Ever Successful Surgery on One-Year-Old Infant

SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…

4 days ago

Manipal Hospital Ghaziabad organises Fire Safety Training to Enhance Emergency Response

Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…

2 weeks ago

Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024

DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…

2 weeks ago

Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…

3 weeks ago

Ankura Hospital Doctors perform a successful Complex Lung Surgery on a 4-month-old Infant

 Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…

3 weeks ago